VRXA insider trading — Veraxa Biotech AG - Post de-SPAC
Over the last 90 days, insiders at Veraxa Biotech AG - Post de-SPAC (VRXA) made 3 open-market purchases worth $93K and 0 open-market sales worth $0, making them net buyers by $93K. The largest purchase was by Baumann Oliver Rolf (Director), who bought 50,000 shares for $75K on Aug 27, 2026. 3 different insiders bought shares in this period — a cluster buy, which many investors watch closely.
Updated Oct 16, 2026.
Recent VRXA insider transactions
Every Form 4 filed by Veraxa Biotech AG - Post de-SPAC officers, directors and 10% owners in the last 90 days, newest first. P = open-market purchase, S = open-market sale; other codes are awards, option exercises, tax withholding or gifts.
| Trade date | Insider | Role | Type | Ownership | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | Hosseinion Warren | Director | P · Purchase | Direct | 6,024 | $1.67 | $10K | Form 4 |
| Aug 27, 2026 | Baumann Oliver Rolf | Director | P · Purchase | Indirect | 50,000 | $1.50 | $75K | Form 4 |
| Aug 27, 2026 | Antz Christoph Rudiger | Chief Executive Officer | P · Purchase | Direct | 5,000 | $1.53 | $8K | Form 4 |
VRXA insider trading FAQ
Are insiders buying VRXA stock?
Yes. In the last 90 days, Veraxa Biotech AG - Post de-SPAC insiders made 3 open-market purchases totaling $93K, and no open-market sales. Purchases with the insider's own money are generally seen as a stronger signal than sales, which happen for many reasons (taxes, diversification, planned 10b5-1 sales).
Who are the insiders trading VRXA?
Recent buyers: Antz Christoph Rudiger, Baumann Oliver Rolf, Hosseinion Warren.
Where does VRXA insider trading data come from?
Every transaction comes from SEC Form 4 filings on EDGAR. Company officers, directors and 10% owners must file a Form 4 within two business days of buying or selling. InsiderBolt reads these filings directly from the SEC.
More stocks with insider activity
Insider trading data is for informational purposes only and is not investment advice. Filings can be amended; always confirm details on SEC EDGAR.